These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25755436)

  • 1. Hemochromatosis gene mutations: prevalence and effects on pegylated-interferon and ribavirin therapy response in chronic hepatitis C in sardinia.
    Sini M; Sorbello O; Civolani A; Demelia L
    J Clin Exp Hepatol; 2012 Sep; 2(3):211-7. PubMed ID: 25755436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
    Ishizu Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1112-6. PubMed ID: 22098610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
    Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C.
    Carneiro MV; Souza FF; Teixeira AC; Figueiredo JF; Villanova MG; Secaf M; Passos AD; Ramalho LN; Carneiro FP; Zucoloto S; Candolo Martinelli AL
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1204-10. PubMed ID: 20555268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The H63D mutation of the hemochromatosis gene is associated with sustained virological response in chronic hepatitis C patients treated with interferon-based therapy: a meta-analysis.
    Li SH; Zhao H; Ren YY; Liu YZ; Song G; Ding P; Ding YP; Wang GQ
    Tohoku J Exp Med; 2012 Apr; 226(4):293-9. PubMed ID: 22499121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
    Bonkovsky HL; Naishadham D; Lambrecht RW; Chung RT; Hoefs JC; Nash SR; Rogers TE; Banner BF; Sterling RK; Donovan JA; Fontana RJ; Di Bisceglie AM; Ghany MG; Morishima C;
    Gastroenterology; 2006 Nov; 131(5):1440-51. PubMed ID: 17101320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of the hemochromatosis gene in prophyria cutanea tarda. Prospective study of 56 cases].
    Skowron F; Bérard F; Grézard P; Wolf F; Morel Y; Perrot H
    Ann Dermatol Venereol; 2001 May; 128(5):600-4. PubMed ID: 11427792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin.
    Coelho-Borges S; Cheinquer H; Wolff FH; Cheinquer N; Krug L; Ashton-Prolla P
    Arq Gastroenterol; 2012; 49(1):9-13. PubMed ID: 22481680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis.
    Negro F; Samii K; Rubbia-Brandt L; Quadri R; Male PJ; Zarski JP; Baud M; Giostra E; Beris P; Hadengue A
    J Med Virol; 2000 Jan; 60(1):21-7. PubMed ID: 10568758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls.
    Holmström P; Marmur J; Eggertsen G; Gåfvels M; Stål P
    Gut; 2002 Nov; 51(5):723-30. PubMed ID: 12377814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.
    Gehrke SG; Stremmel W; Mathes I; Riedel HD; Bents K; Kallinowski B
    J Mol Med (Berl); 2003 Dec; 81(12):780-7. PubMed ID: 14557859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HFE genotype in patients with hemochromatosis and other liver diseases.
    Bacon BR; Olynyk JK; Brunt EM; Britton RS; Wolff RK
    Ann Intern Med; 1999 Jun; 130(12):953-62. PubMed ID: 10383365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C.
    Sikorska K; Stalke P; Romanowski T; Rzepko R; Bielawski KP
    Hepatobiliary Pancreat Dis Int; 2013 Aug; 12(4):377-84. PubMed ID: 23924495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis.
    Ladero JM; Ropero P; Ortega L; Taxonera C; González FA; López-Alonso G; Briceño O; Rodríguez-Agulló JL; González L; Villegas A; Díaz-Rubio M
    Rev Esp Enferm Dig; 2003 Dec; 95(12):829-36. PubMed ID: 14972004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron overload and HFE gene mutations in Polish patients with liver cirrhosis.
    Sikorska K; Romanowski T; Stalke P; Iżycka-Świeszewska E; Bielawski KP
    Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):270-5. PubMed ID: 21669570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C.
    Geier A; Reugels M; Weiskirchen R; Wasmuth HE; Dietrich CG; Siewert E; Gartung C; Lorenzen J; Bosserhoff AK; Brügmann M; Gressner AM; Matern S; Lammert F
    Liver Int; 2004 Aug; 24(4):285-94. PubMed ID: 15287851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection.
    Distante S; Bjøro K; Hellum KB; Myrvang B; Berg JP; Skaug K; Raknerud N; Bell H
    Liver; 2002 Jun; 22(3):269-75. PubMed ID: 12100578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.